RxDoctor Payments Data

Saleh Khaddash, MD

Endocrinology · Clifton, NJNPI 1174551824

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.

$1,808in general payments, 2019–2025

Across 32 payments — averaging $56.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$389
  • Medtronic$263
  • Sanofi-aventis U.S. LLC$244
  • Madrigal Pharmaceuticals$211
  • Gilead$125
  • Exact Sciences$125
  • plus $451 from 7 others

What the payments were for

  • Food & beverage$1,69994%
  • Education$684%
  • Other$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ironwood Pharmaceuticals, Inc3$389
Medtronic(2 entities)3$263
Sanofi-aventis U.S. LLC2$244
Madrigal Pharmaceuticals4$211
Gilead1$125
Exact Sciences1$125
AbbVie1$125
Abbott5$97
Amgen4$73
Novo Nordisk2$45
Lilly USA, LLC3$43
RGH Enterprises LLC2$39
Pfizer1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$172,809
Medicare patients
361
Services billed
1,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin756$848,314
OzempicSemaglutide592$745,765
JanuviaSitagliptin Phosphate537$521,485
JanumetSitagliptin Phos/Metformin Hcl421$397,482
TrulicityDulaglutide109$188,519
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog328$121,574
Lantus SolostarInsulin Glargine,hum.Rec.Anlog715$86,656
FarxigaDapagliflozin Propanediol88$83,955
Humalog Kwikpen U-100Insulin Lispro386$82,533
MounjaroTirzepatide47$82,452
TradjentaLinagliptin62$70,008
Insulin Lispro Kwikpen U-100Insulin Lispro333$66,355
Fiasp FlextouchInsulin Aspart (Niacinamide)78$56,537
Novolog FlexpenInsulin Aspart286$48,921
RybelsusSemaglutide33$40,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$45$792,529655 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25$43$288,260241 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$244$16,47120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other endocrinology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →